Marksans Pharma has received Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) for its Goa facility which was inspected between April 3 and April 7, 2017.
Marksans Pharma is engaged in production of prescription drugs, caters in areas like oncology, gastroenterology, antidiabetic, cardiovascular, pain management, gynaecology and others.